Furazolidone metabolite (CPAOZ) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Furazolidone metabolite (CPAOZ) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to food safety diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-79-1 | 1. BSA-Furazolidone metabolite (CPAOZ) 2. Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody | $2709.00 |
GMP-SMT-79-2 | 1. OVA-Furazolidone metabolite (CPAOZ) 2. Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody | $2709.00 |
GMP-SMT-79-3 | 1. BSA-Furazolidone metabolite (CPAOZ) 2. Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody | $2709.00 |
GMP-SMT-79-4 | 1. OVA-Furazolidone metabolite (CPAOZ) 2. Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody | $2709.00 |
GMP-SMT-79-Ag-1 | BSA-Furazolidone metabolite (CPAOZ) | $756.00 |
GMP-SMT-79-Ag-2 | OVA-Furazolidone metabolite (CPAOZ) | $756.00 |
GMP-SMT-79-Ab-1 | Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody | $1953.00 |
GMP-SMT-79-Ab-2 | Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Furazolidone metabolite (CPAOZ)
Cat No. | GMP-SMT-79-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Furazolidone metabolite (CPAOZ) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Furazolidone metabolite (CPAOZ) had been validated with our anti-Hapten antibody Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Furazolidone metabolite (CPAOZ)
Cat No. | GMP-SMT-79-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Furazolidone metabolite (CPAOZ) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Furazolidone metabolite (CPAOZ) had been validated with our anti-Hapten antibody Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Furazolidone metabolite (CPAOZ) mouse monoclonal antibody
Cat No. | GMP-SMT-79-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.50 |
Products description | The anti-Hapten antibody against hapten Furazolidone metabolite (CPAOZ) had been validated with our hapten hapten-carrier conjugates BSA-Furazolidone metabolite (CPAOZ) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Furazolidone metabolite (CPAOZ) human monoclonal antibody
Cat No. | GMP-SMT-79-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.50 |
Products description | The anti-Hapten antibody against hapten Furazolidone metabolite (CPAOZ) had been validated with our hapten hapten-carrier conjugates BSA-Furazolidone metabolite (CPAOZ) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Biomarker Information
Basic Orange (BO/CSD) is a cationic dye that belongs to the xanthene family, specifically classified as a basic dye. It is widely utilized as a coloring agent in various industrial sectors, including textiles, paper manufacturing, and plastic production. BO/CSD possesses a unique chemical structure consisting of a pyridine ring and an amino group (-NH2), with variations in the substituents attached to the pyridine ring determining its specific properties and applications.
The widespread use of BO/CSD has raised concerns regarding its potential impacts on both human health and the environment. As a result, it has become crucial to comprehensively analyze its behavior, fate, and associated risks in order to establish appropriate management strategies.
A primary concern associated with BO/CSD is its potential to contaminate water bodies, such as surface water and groundwater. Industrial effluents that contain BO/CSD may be discharged into rivers, lakes, and oceans, leading to the pollution of aquatic environments. Additionally, improper waste disposal practices or accidental spills can result in the leaching of BO/CSD into the soil, potentially contaminating groundwater aquifers.
BO/CSD is known for its persistence in the environment, meaning it can persist for long periods without significant degradation. This characteristic increases the likelihood of accumulation in various environmental compartments and raises concerns about its long-term impacts on ecosystems. Furthermore, BO/CSD's resistance to degradation can result in its bioaccumulation in organisms, posing risks to higher trophic levels within the food chain.
Monitoring the levels of BO/CSD in environmental samples is essential to assess its potential risks to human health and ecosystems. Regular monitoring programs help identify pollution sources, track contamination trends, and evaluate the effectiveness of pollution control measures. By measuring BO/CSD concentrations in water, soil, sediment, and biota, regulatory agencies can obtain valuable insights into the extent and distribution of contamination.
Various analytical techniques play a crucial role in quantifying BO/CSD concentrations in environmental samples. Spectrophotometry, which utilizes absorption or emission measurements, is commonly employed for rapid and cost-effective analysis of BO/CSD levels. High-performance liquid chromatography (HPLC) is another widely used technique that provides accurate and precise measurements of BO/CSD concentrations in complex environmental matrices. Additionally, fluorescence spectroscopy offers sensitivity and selectivity for detecting and quantifying BO/CSD in environmental samples.
In order to protect human health and the environment, it is necessary to implement appropriate management strategies to mitigate BO/CSD contamination. This includes promoting sustainable practices in industrial processes, improving wastewater treatment technologies, and implementing strict regulations on the use and disposal of products containing BO/CSD. By adopting such measures, it is possible to minimize the release of BO/CSD into the environment and reduce the potential risks associated with its presence.
It is worth noting that research on the toxicity of BO/CSD has indicated potential risks to both aquatic organisms and human health. Studies suggest that exposure to BO/CSD can lead to toxic effects on fish, algae, and other aquatic organisms, causing changes in behavior, growth, and reproduction. Prolonged exposure to BO/CSD has also been associated with skin irritation, respiratory problems, and other health issues in humans. Furthermore, the breakdown products of BO/CSD in the environment may be more toxic than the original dye, amplifying the potential health risks.
In conclusion, Basic Orange (BO/CSD) is an extensively utilized cationic dye in various industrial applications. Its potential impacts on human health and the environment necessitate careful monitoring and management. Regular monitoring programs, along with the application of analytical techniques, are crucial for assessing contamination levels, identifying pollution sources, and developing effective strategies to mitigate the risks associated with BO/CSD. By adopting sustainable practices, improving wastewater treatment technologies, and implementing stringent regulations, it is possible to minimize the environmental and health risks posed by BO/CSD contamination and ensure the long-term well-being of ecosystems and human populations.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.